商品名：Droxia and Hydrea (Canada)
Antineoplastic agent. Hydroxyurea is a cell-cycle–dependent agent, acting primarily at the S-phase of mitosis. Exact mechanism of action is uncertain, but it may interfere with DNA synthesis in cancer cells. The specific effects on red blood cells (RBCs) occur because of the activity on hemoglobin.
In people, hydroxyurea is used for treatment of sickle cell anemia and occasionally other carcinomas. In animals it has been used in combination with other anticancer modalities for treatment of certain tumors. In animals one of the uses has been treatment of polycythemia vera.
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
精確產品／合格危害調劑品、物種、紅血球增多類型／可逆病因或具名腫瘤方案、PCV／HCT 與血球目標、放血計畫、CBC／分類／platelet 與 hold 規則、腎肝與感染、MetHb 監測、繁殖狀態、雙人複核及危害處理完成前封鎖執行。
依出現頻率分組；嚴重副作用獨立列出，臨床上需立即辨識。
renal